CClinicalTrials.gg
RecruitingNCT06314477Updated Sep 21, 2026

Effect of CPAP Treatment in Patients With Severe Uncontrolled Asthma: The ASTHMA-SLEEP Trial

An interventional study of CPAP treatment and Hygienic and dietary advice in Obstructive Sleep Apnea and Asthma, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate the impact of CPAP treatment on asthma control in patients with severe uncontrolled asthma and obstructive sleep apnea (OSA)

Read the detailed description

Background: The prevalence of obstructive sleep apnea (OSA) is high in patients with severe uncontrolled asthma and can worsen asthma control. Previous observational studies demonstrated that CPAP treatment could improve control in patients with mild-moderate asthma. Nevertheless, there are no studies in patients with severe uncontrolled asthma.

Primary objective: To evaluate the impact of CPAP treatment on asthma control in patients with severe uncontrolled asthma and OSA.

Methodology: Multicenter, prospective, randomized, controlled clinical trial with parallel groups in subjects with severe uncontrolled asthma who are older than 18 years and without sleepiness (Epworth sleepiness scale score ≤10). All included subjects will undergo conventional polysomnography and those with an apnea-hypopnea index (AHI) ≥15/hour will be randomized in a 1:1 ratio to receive conservative treatment or conservative treatment plus CPAP. Monitoring will be carried out during12 months. Patients will be evaluated at inclusion, at 1 month, 6 and 12 months.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Asthma
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age >18 years
  • Diagnosis of severe uncontrolled asthma according to the criteria of the Spanish Asthma Management Guide (GEMA) or the Global Initiative for Asthma (GINA) and no hospitalizations the month prior to inclusion in the study.
  • Apnea hypopnea rate greater than or equal to 15/hour
  • Punctuation in the Epworth Sleepiness Scale ≤10
  • Obtaining informed consent.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with CPAP
  • Patient with central sleep apnea or Cheyne-Stokes respiration
  • Other sleep disorders: narcolepsy, restless leg syndrome, chronic insomnia,
  • Resistant hypertension
  • Active Smoking
  • Unstable comorbidities or medications may interfere with asthma control
  • Pregnancy
  • Any process that reduces life expectancy to \<1 year,
  • Any medical or social factor that may limit CPAP compliance
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
138 participants (estimated)

Study arms

  • Active comparator
    Conservative treatment

    Subjects allocated to this arm will receive hygienic and dietary measures counselling

    Other: Hygienic and dietary advice

  • Experimental
    CPAP treatment

    Subjects allocated to this arm will receive treatment with continuous positive airway pressure (CPAP)

    Device: CPAP treatment

Interventions

  • DeviceCPAP treatment

    Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)

  • OtherHygienic and dietary advice

    Subjects allocated to this arm will receive hygienic and dietary counselling

05

What researchers measure

Primary outcomes

  1. Asthma control questionnaire

    To evaluate the impact of CPAP treatment on asthma control based on the Asthma control questionnaire (ACQ)

    Time frame: 12 months

  2. Asthma control test

    To evaluate the impact of CPAP treatment on asthma control based on the Asthma control test (ACT)

    Time frame: 12 months

Secondary outcomes

  1. Lung function- forced expiratory volume in the first second (FEV1) in spirometry

    To evaluate the impact of CPAP treatment on FEV1 (ml) on spirometry

    Time frame: 12 months

  2. Lung function-forced vital capacity (FVC) in spriometry

    To evaluate the impact of CPAP treatment on FVC (ml) on spirometry

    Time frame: 12 months

  3. Prevalence of OSA in severe uncontrolled asthma

    Determine the prevalence of OSA in patients with severe uncontrolled asthma

    Time frame: Baseline

  4. Inflammatory profile

    Plasma proteins from peripheral blood samples will be used to analyze an inflammatory panel using a high-throughput, multiplex immunoassay technology based on Proximity Extension Assays (PEA) at baseline and after CPAP treatment

    Time frame: Baseline, 6 and 12 months

  5. Quality of life (Abbreviated Asthma Quality of life Questionnaire- mini-AQLQ questionnaire)

    Study whether OSA ans its treatment affects quality of life in subjects with severe uncontrolled asthma based on the punctuation obtained in the mini-AQLQ questionnaire. Higher scores indicate better quality of life

    Time frame: 12 months

  6. Exacerbations

    Number of excarbations the year before starting the study and at 12-month of treatment in both arms

    Time frame: From enrollment to the end of the study at 12 months

06

Study locations

1 of 1 sites recruiting
  • Hospital Clinic Barcelona
    Barcelona, Spain 08036, Spain
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Anonymized IPD will be available upon reasonable request following publication of the study results. Requests will be valuated by the study team and be subject to applicable ethical, legal and data portection requeriments.

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06314477
Lead sponsor
Hospital Clinic of Barcelona
Responsible party
Mireia Dalmases (Principal investigator, Hospital Clinic of Barcelona) — Principal investigator
First posted
Mar 18, 2024
Start date
Feb 29, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Mireia Dalmases, MD
Contact
mdalmase@clinic.cat
+34932275746
Mireia Dalmases, MD
principal investigator · Hospital Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion